ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 08 | February 21, 2003

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Group, Center Clinical Trials Listed

May 25, 2007

A Special Report: Language With A Purpose–von Eschenbach’s Four Years at NCI.

May 19, 2006

Quality Oncology Wins Pilot Contract For Cancer Management In Fla.

July 27, 2001

Hagop Kantarjian: Why Drugs Cost Too Much and How Prices Can be Brought Down

May 31, 2013

Cancer Policy; Cost Containment Impedes Research, Cancer Panel Finds

October 17, 1997

NCI Objections Delay GAO Report On Cancer Control

March 7, 1980